SARS-CoV-2 Vaccines Development: Genetic Vaccines

Sarah Issa, Dr Daniela Ovadia, Agenzia Zoe

December 09, 2020

DNA vaccines are based on plasmid DNA that can be produced at a large scale in bacteria and contain expression promoters and the gene that encodes the spike protein. The advantage of these technologies is the possibility of large-scale production as well as the high stability of plasmid DNA.

Part 1: SARS-CoV-2 Vaccines Development: An Overview
Part 2: Inactivated Vaccines
Part 3: Protein-based Vaccines
Part 4: Viral Vectors
Part 6: Monoclonal Antibodies

This is a snapshot of emerging vaccines during a rapidly evolving pandemic. Any and all information currently available related to COVID-19 is subject to change as more details become available. 

This article originally appeared on Univadis, part of the Medscape Professional Network. 



Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: